Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Olga Wasile

Family Medicine Chugiak, AK Medical Doctor

NPI 1306952569 CMS profile 285615

20905 Eastside Drive #1, Chugiak, AK 99567

Open in the dashboard

General payments

$880

40 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Olga Wasile of Chugiak, AK is reported in the CMS Open Payments database as having received $880 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $113 4
2023 General $126 5
2022 General $301 11
2021 General $242 15
2020 General $99 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olga Wasile
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Olga Wasile were reported at $113. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Olga Wasile Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $99 $120 $32–$415 $114
2021 $242 $137 $35–$551 $132
2022 $301 $137 $37–$512 $149
2023 $126 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $113 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $366 13 payments
  2. AstraZeneca Pharmaceuticals LP $114 4 payments
  3. Pfizer Inc. $80 4 payments
  4. Allergan Inc. $48 2 payments
  5. Amarin Pharma Inc. $47 3 payments
  6. Idorsia Pharmaceuticals US Inc $42 2 payments
  7. Eisai Inc. $36 3 payments
  8. Merck Sharp & Dohme Corporation $33 2 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $20 1 payment
  10. Nestle HealthCare Nutrition Inc. $19 1 payment
  11. Other $75 5 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $880 40 payments
Products named General payments · program years 2020–2025
  1. UBRELVY Neuroscience $278 10 payments
  2. VRAYLAR $88 3 payments
  3. ELIQUIS $80 4 payments
  4. BREZTRI $80 2 payments
  5. UBRELVY Neuroscience $48 2 payments
  6. Vascepa $47 3 payments
  7. QUVIVIQ $42 2 payments
  8. XIFAXAN $41 2 payments
  9. Dayvigo $36 3 payments
  10. AIRSUPRA $34 2 payments
  11. Other $294 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

1,324

Median for Family Practice: 1,826

Drug cost

$60,064

Median for Family Practice: $120,094

Branded share of claims

18.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 16 $20,635
Belsomra Suvorexant Brand 18 $11,896
Farxiga Dapagliflozin Propanediol Brand 20 $6,127
Candesartan Cilexetil Generic 20 $2,850
Carvedilol Er Carvedilol Phosphate Brand 23 $2,729
Synthroid Levothyroxine Sodium Brand 15 $1,963
Atorvastatin Calcium Generic 73 $1,147
Albuterol Sulfate Hfa Albuterol Sulfate Brand 37 $1,041
Celecoxib Generic 14 $762
Lisinopril Generic 68 $761

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$46,437

Medicare's payments for the services billed

Medicare patients

281

Average age 73

Services billed

717

176 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 38%
Diabetes 23%
Ischemic heart disease 19%
Atrial fibrillation 13%
Cancer 12%
Depression 12%
Chronic kidney disease 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record